Guardant Health (GH)
Blood and tissue cancer tests spanning screening, monitoring, and treatment selection.
$177.55
vs last close+0.39 (+0.22%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 97.31% | 130.59M shares | |
|---|---|---|---|
| 625 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.88% | 3.86M shares | |
| 18 holders · as of Sep 22, 2026 | |||
| Adds to | 100.19% | ||
134.20M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 100.19%; nothing is left for Other.
13F, as of Jun 30, 2026
625 holders · 130.59M shares · 158 new positions · 354 increased · 189 reduced · 47 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.62M | 5.68% | −3.93M | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 6.51M | 4.85% | −508.7K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 5.76M | 4.29% | +131.7K | Aug 13, 2026 |
| FMR LLC | 5.49M | 4.09% | +1.37M | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 5.45M | 4.06% | −392.2K | Aug 13, 2026 |
| Invesco Ltd. | 4.43M | 3.30% | −516.7K | Aug 14, 2026 |
| Goldman Sachs Group Inc | 3.78M | 2.81% | −659.9K | Aug 14, 2026 |
| Two Sigma Investments, LP | 3.72M | 2.77% | −510.2K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Wellington Group Holdings LLPincl. Wellington Management Company LLP, Wellington Management Group LLP +1 more | 8.23% | 10.13M | 13G | Nov 8, 2024 |
| BlackRock, Inc. | 7.50% | 9.29M | 13G | Apr 17, 2025 |
| Cadian Capital Management GP, LLCincl. Cadian Capital Management, LP, Eric Bannasch | 5.70% | 7.01M | 13G | Nov 13, 2024 |
| T. Rowe Price Associates, Inc. | 5.40% | 7.04M | 13G | May 15, 2026 |
| Deep Track Biotechnology Master Fund, Ltd.incl. David Kroin, Deep Track Capital, LP | 5.35% | 6.58M | Oct 7, 2024 | |
| Vanguard Capital Management | 5.02% | 6.59M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 16, 2026 | Musa Tariqdirector | Sale | 116 | $175.00 | 11,449 |
| Sep 16, 2026 | Alex M. II Azardirector | Sale | 826 | $175.00 | 825 |
| Sep 16, 2026 | Steve E. Krognesdirector | Sale · 4 lots | 6,674 | $175.74 | 7,906 |
| Sep 15, 2026 | Darya Chudovaofficer: Chief Technology Officer | Sale | 7,738 | $178.00 | 70,635 |
| Sep 11, 2026 | Kumud Kaliaofficer: Chief Information Officer | Sale | 4,000 | $158.05 | 39,794 |
| Aug 21, 2026 | AmirAli Talasazdirector, officer: Co-Chief Executive Officer | Sale · 3 lots | 37,500 | $169.16 | 37,500 |
| Aug 17, 2026 | Musa Tariqdirector | Sale | 116 | $156.45 | 11,316 |
| Aug 12, 2026 | Terilyn J. Monroeofficer: Chief People Officer | Sale · 5 lots | 46,300 | $165.12 | 22,979 |
| Aug 10, 2026 | Chris Freemanofficer: Chief Commercial Officer | Sale · 4 lots | 63,605 | $169.58 | 65,374 |
| Aug 5, 2026 | Medina Manuel Hidalgodirector | Sale · 2 lots | 1,700 | $164.24 | 4,556 |
House and Senate disclosures
Not reported.